Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × defactinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7 Ovarian Neoplasms 4 Mesothelioma, Malignant 4 Carcinoma, Non-Small-Cell Lung 3 Neoplasms 2 Mesothelioma 2 Lung Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Phase IB 1 Neoplasms, Mesothelial 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Endometrioid 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenoma 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 129 Gemcitabine 115 Capecitabine 107 Fluorouracil 99 Paclitaxel 98 Bevacizumab 91 Oxaliplatin 89 Nivolumab 86 Leucovorin 81 Docetaxel 80 Radiosurgery 79 Irinotecan 72 Carboplatin 70 Cisplatin 69 Cetuximab 61 Cyclophosphamide 60 Magnetic Resonance Spectroscopy 59 Specimen Handling 54 Biopsy 53 Radiotherapy 48 Trastuzumab 47 Ipilimumab 44 Drug Therapy 43 Pemetrexed 38 Everolimus 38 Albumin-Bound Paclitaxel 37 130-nm albumin-bound paclitaxel 37 Fulvestrant 36 Doxorubicin 34 aldesleukin 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05669482 2025-09-02

RAMP205

Verastem, Inc.

Phase 1/2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡